- Home
- BKYI
as of 03-06-2026 3:26pm EST
$0.65
$0.05
-6.80%
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | HOLMDEL |
| Market Cap: | 8.3M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 243.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $1.97 | Next Earning Date: | 06-11-2026 |
| Revenue: | $6,302,984 | Revenue Growth: | 111.81% |
| Revenue Growth (this year): | 7.45% | Revenue Growth (next year): | 23.29% |
| P/E Ratio: | -69.84 | Index: | N/A |
| Free Cash Flow: | -2927119.0 | FCF Growth: | N/A |
AI-Powered BKYI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.70%
70.70%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 4, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 4, 2026 · 100% conf.
AI Prediction BUY
1D
-3.64%
$0.67
5D
+9.29%
$0.77
20D
-10.81%
$0.62
Price: $0.70 Prob +5D: 100% AUC: 1.000
0001437749-26-006816
bkyi20260302_8k.htm
false 0001019034
0001019034
2026-03-03 2026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2026
BIO-key International, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-13463
(Commission File Number)
41-1741861
(I.R.S. Employer Identification No.)
101 CRAWFORDS CORNER ROAD, SUITE 4116,
HOLMDEL, NJ 07733
(Address of principal executive offices)
(732) 359-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BKYI
Nasdaq Capital market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 3, 2026 BIO-key International, Inc. (the “Company”) issued a press release containing financial results for its year end 2025 cash position. A copy of the press release issued by the Company on March 3, 2026 is attached as Exhibit 99.
The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibit.
(d)
Exhibits. The following exhibit is furnished herewith:
99.1
Press Release, dated March 3, 2026 issued by the Company.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-KEY INTERNATIONAL, INC.
Date: March 4, 2026
By:
/s/ Cecilia C. Welch
Cecilia C. Welch
Chief Financial Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release, dated March 3, 2026 issued by the Company.
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 14, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 14, 2025 · 100% conf.
AI Prediction SELL
1D
-2.93%
$0.92
5D
-5.62%
$0.90
20D
-9.70%
$0.86
Price: $0.95 Prob +5D: 0% AUC: 1.000
0001437749-25-034997
bkyi20251113_8k.htm
false 0001019034
0001019034
2025-11-14 2025-11-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2025
BIO-key International, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-13463
(Commission File Number)
41-1741861
(I.R.S. Employer Identification No.)
101 CRAWFORDS CORNER ROAD, SUITE 4116,
HOLMDEL, NJ 07733
(Address of principal executive offices)
(732) 359-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BKYI
Nasdaq Capital market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2025 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter 2025. A copy of the press release issued by the Company on November 14, 2025 is attached as Exhibit 99.
The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibit.
(d)
Exhibits. The following exhibit is furnished herewith:
99.1
Press Release, dated November 14, 2025, issued by the Company.
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-KEY INTERNATIONAL, INC.
Date: November 14, 2025
By: /s/ Cecilia C. Welch
Cecilia C. Welch
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
99.1
Press Release, dated November 14, 2025 issued by the Company.
2025 Q2 Q2 2025 Earnings
8-K Aug 13, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 13, 2025
0001437749-25-026360
bkyi20250812_8k.htm
false 0001019034
0001019034
2025-08-13 2025-08-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2025
BIO-key International, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-13463
(Commission File Number)
41-1741861
(I.R.S. Employer Identification No.)
101 CRAWFORDS CORNER ROAD, SUITE 4116,
HOLMDEL, NJ 07733
(Address of principal executive offices)
(732) 359-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock
BKYI
Nasdaq Capital market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On August 13, 2025 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter 2025. A copy of the press release issued by the Company on August 13, 2025 is attached as Exhibit 99.
The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01.
Financial Statements, Pro Forma Financial Information and Exhibit.
(d)
Exhibits. The following exhibit is furnished herewith:
99.1
Press Release, dated August 13, 2025, issued by the Company.
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-KEY INTERNATIONAL, INC.
Date: August 13, 2025
By:
/s/ Cecilia C. Welch
Cecilia C. Welch
Chief Financial Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release, dated August 13, 2025 issued by the Company.
Latest BIO-key International Inc. News
BKYI Breaking Stock News: Dive into BKYI Ticker-Specific Updates for Smart Investing
GlobeNewswire
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients
📈
AI Sentiment
Highly Positive
9/10
Compare BKYI vs Leading Stocks
See how BKYI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BKYI BIO-key International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.